News 26 April 2017

Valneva Reports Best Results in the Company’s History in 2016

The company member of Atlanpole reports best FY results in the company’s history with its first year of Positive EBITDA in 2016.

Valneva, a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, reported today its fourth quarter and full year financial results ending December 31, 2016.

The company expects to continue showing a strong financial performance in 2017.

  • Total revenues and grants of €97.9 million in 2016 (vs €83.3 million in 2015) driven mainly by a 73.1% increase in IXIARO®/JESPECT® revenues;
  • Valneva reported a positive EBITDA of €2.8 million in 2016 (vs. an EBITDA loss of €8.5 million in 2015);

Read the press release.

Back to news